首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1739544

2026 年至 2032 年人工心臟市場類型、技術、最終用戶和地區分佈

Artificial Heart Market By Type (Total Artificial Hearts, Left Ventricular Assist Devices ), Technology, End-User (Hospitals, Ambulatory Surgical Centers ), & Region for 2026-2032

出版日期: 2025年05月09日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年人工心臟市場估值

人工心臟的需求正在迅速成長，這主要是由於全球心血管疾病的發生率不斷上升。心臟衰竭通常由冠狀動脈疾病、高血壓和心臟病發作等疾病引起，並且隨著世界人口老化和生活方式相關健康問題的增加而變得越來越普遍。遺憾的是，用於移植的捐贈心臟供應有限，導致需要器官的人數與可用器官數量之間存在巨大差距。因此，預計該市場銷售額將在2024年超過25.9億美元，並在2032年達到約73.4億美元的估值。

技術突破也大大促進了人工心臟需求的成長。材料科學、微型化和生物相容性的進步，為更精密、更能模擬自然心臟活動的人工心臟鋪平了道路。這些技術創新透過最大限度地減少問題並延長設備使用壽命，改善了患者的生活品質，使市場在2026年至2032年間的複合年成長率達到13.92%。

人工心臟市場定義/概述

人工心臟是一種機械裝置，可以暫時或永久地取代衰竭的人類心臟，維持身體的血液流動和氧氣供應。人工心臟主要用於患有嚴重心臟病（例如末期心臟衰竭）的患者，這些患者的心臟無法再有效地泵血。人工心臟透過循環系統泵血，複製自然心臟的功能，確保重要器官獲得正常運作所需的氧氣和營養。

人工心臟是一種革命性的醫療設備，它可以取代衰竭的人類心臟功能，為患有嚴重心臟疾病的患者提供挽救生命的支持。人工心臟的一個重要應用是作為心臟移植的過渡。當末期心臟衰竭患者的心臟無法正常泵血時，人工心臟可以暫時取代衰竭的器官。這使得患者在等待移植心臟的過程中能夠存活下來。

未來機械心臟的應用可望徹底改變循環系統，為嚴重心臟疾病患者帶來新的希望。隨著全球心臟病負擔的不斷加重，對於那些因醫療原因（例如缺乏捐贈器官）無法接受心臟移植的患者來說，人工心臟正成為一個越來越重要的選擇。這些人工心臟的設計工作原理與自然心臟相似，能夠將血液泵送到全身，延長心臟功能。

它的目的是將血液泵送到全身，即使病人自己的心臟停止運作，也能延長生命。

心血管疾病發生率的上升會推動人工心臟市場的發展嗎？

心血管疾病 (CVD) 發生率的上升是人工心臟市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，心血管疾病是全球首要的死亡原因，每年約導致 1,790 萬人死亡。這佔全球整體的 31%。心血管疾病的盛行率持續上升，尤其是在中低收入國家，這些國家佔心血管疾病死亡人數的 75% 以上。根據美國疾病管制與預防中心 (CDC) 的數據，光是在美國，心臟病就是首要的死亡原因，每年約導致 655,000 人死亡（四分之一的死亡人數）。

心血管疾病 (CVD) 盛行率的驚人上升預計將增加對人工心臟的需求，因為人工心臟是終末期心臟衰竭患者的救命治療方法。根據美國心肺血液研究所 (NHLBI) 的估計，美國約有 620 萬成年人心臟衰竭，預計到 2030 年將增加至 800 多萬人。此外，器官共享美國網路 (UNOS) 報告稱，截至 2021 年，美國有超過 3,500 人在等待心臟移植。由於捐贈心臟持續短缺，人工心臟成為移植的重要過渡選擇，或在某些情況下作為最終治療手段。

高成本會阻礙人工心臟市場的發展嗎？

人工心臟的高成本是其市場拓展的主要障礙，並可能限制其廣泛採用和普及。據美國國立衛生研究院 (NIH) 稱，人工心臟植入物的總成本（包括裝置和相關醫療費用）在 15 萬至 50 萬美元之間。許多患者和醫療保健系統，尤其是在開發中國家和地區，輔助人工心臟(VAD)，但完整的人工心臟植入物通常不在保險範圍內，這進一步限制了經常需要此類手術的老年患者獲得此類服務。

高成本對該領域的研發以及病患的用藥管道都產生了影響。食品藥物管理局(FDA) 聲稱，人工心臟核准所需的漫長臨床試驗耗資數億美元，阻礙了一些公司進入市場或開發創新設計。如此高的進入門檻可能會抑制技術發展、阻礙競爭，並導致長期高成本。此外，美國國家心肺血液研究所 (NHLBI) 表示，儘管近年來政府對人工心臟研究的資助有所增加，但仍不足以刺激該領域的快速創新和成本降低。

SynCardia Systems, LLC
Carmat
Abiomed
CryoLife, Inc.
ReinHeart TAH GmbH
Jarvik Heart, Inc.
Calon Cardio-Technology Ltd.
BiVACOR, Inc.
CARMAT SA
MyLVAD
Thoratec Corporation
Cirtec
Abbott
ON-X LIFE TECHNOLOGIES, INC.
ABIOMED
Cleveland Heart, Inc.
Tianjin Medical
Braile Biomedica
Edwards Lifesciences
R. Bard, Inc.
Terumo Corporation
MAQUET GmbH & Co. KG
Sorin Group
Medtronic, Inc.

第11章市場展望與機會

新興技術
未來市場趨勢
投資機會

第12章附錄

簡稱列表
來源和參考文獻

簡介目錄

Product Code: 54709

Artificial Heart Market Valuation - 2026-2032

The demand for artificial hearts is quickly expanding owing mostly to the rising global frequency of cardiovascular disorders. Heart failure which is frequently caused by illnesses such as coronary artery disease, high blood pressure, and heart attacks is growing increasingly widespread as the world's population ages and lifestyle-related health issues increase. Unfortunately, the supply of donor hearts for transplantation is limited resulting in a considerable disparity between the number of people in need and the organs available by enabling the market to surpass a revenue of USD 2.59 Billion valued in 2024 and reach a valuation of around USD 7.34 Billion by 2032.

Technological breakthroughs are also contributing significantly to the growing demand for artificial hearts. Materials science, downsizing, and biocompatibility advancements are paving the way for more sophisticated artificial hearts that can better replicate natural cardiac activities. These innovations improve patient's quality of life by minimizing problems and increasing the device's lifespan by enabling the market to grow at a CAGR of 13.92% from 2026 to 2032.

Artificial Heart Market: Definition/ Overview

An artificial heart is a mechanical device that replaces a failing human heart, either temporarily or permanently, to keep blood flowing and oxygen delivered to the body. It is primarily used in individuals with severe heart diseases including as end-stage heart failure in which the heart is no longer able to efficiently pump blood. The artificial heart replicates the natural heart's function by pumping blood through the circulatory system ensuring that essential organs receive the oxygen and nutrition they require to function.

The artificial heart is a groundbreaking medical device that replaces the function of a failing human heart providing life-saving support to patients suffering from serious cardiac diseases. One of the key uses for artificial hearts is as a bridge to heart transplantation. An artificial heart can temporarily replace the failing organ in individuals with end-stage heart failure in which the heart can no longer adequately pump blood. This enables patients to survive while awaiting a donor heart for transplantation.

The future usage of mechanical hearts has the potential to change cardiology providing new hope to patients with serious cardiac diseases. As the global burden of heart disease rises, artificial hearts are becoming an increasingly important option for patients who are unable to receive heart transplants due to a lack of donor organs or other medical reasons. These devices are designed to perform similarly to a natural heart moving

blood throughout the body and prolonging life when the patient's own heart is no longer functioning.

Will the Rising Incidence of Cardiovascular Diseases Drive the Artificial Heart Market?

The increasing incidence of cardiovascular diseases (CVDs) is a major driver of the artificial heart market. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of mortality worldwide, killing an estimated 17.9 million people each year. This accounts for 31% of all deaths globally. CVD prevalence has continuously increased, particularly in low- and middle-income nations which account for more than 75% of CVD deaths. In the United States alone, the Centers for Disease Control and Prevention (CDC) says that heart disease is the leading cause of death accounting for around 655,000 fatalities yearly or one in every four deaths.

This worrying rise in CVD prevalence is predicted to increase demand for artificial hearts as a life-saving treatment for individuals with end-stage heart failure. The National Heart, Lung, and Blood Institute (NHLBI) estimates that roughly 6.2 million adults in the United States have heart failure with projections indicating that this figure could rise to over 8 million by 2030. Furthermore, the United Network for Organ Sharing (UNOS) reports that as of 2021, there were over 3,500 people on the waiting list for a heart transplant in the United States. Given the ongoing paucity of donor hearts, artificial hearts serve as an important bridge-to-transplant option or, in certain situations, a destination therapy.

Will the High-Cost Hamper the Artificial Heart Market?

The high cost of artificial hearts poses a substantial barrier to market expansion, potentially limiting adoption and accessibility. According to the National Institute of Health (NIH), the overall cost of an artificial heart transplant including the device and related medical care can range between $150,000 and $500,000. Many patients and healthcare systems, particularly in developing countries or locations with low healthcare resources are unable to afford mechanical hearts due to the significant financial load. According to the Centers for Medicare and Medicaid Services (CMS), while they cover certain ventricular assist devices (VADs) for qualifying beneficiaries, full artificial heart transplants are not usually reimbursed, further limiting access for elderly patients who frequently require such operations.

The high cost has an impact not just on patient access but also on research and development in the sector. The Food and Drug Administration (FDA) has claimed that the long clinical trials required for artificial heart approval can cost manufacturers hundreds of millions of dollars discouraging some companies from joining the market or developing novel designs. This expensive barrier to entry may stifle technological developments and hinder competition, thus maintaining high costs in the long run. Furthermore, the National Heart, Lung, and Blood Institute (NHLBI) has stated that, while government funding for artificial heart research has increased in recent years, it remains insufficient to encourage rapid innovation and cost reduction in the sector.

Category-Wise Acumens

Will Broader Application and Widespread Adoption Drive Growth in the Type Segment?

Left Ventricular Assist Devices (LVADs) are in a dominant position owing to their broad application and widespread adoption in treating patients with severe heart failure. LVADs are intended to support the left ventricle, the heart's major pumping chamber responsible for delivering oxygen-rich blood to the body. These devices are frequently utilized as a bridge to heart transplantation providing critical-care patients with the essential assistance while they wait for a donor heart. Furthermore, LVADs are increasingly being used as destination therapy for patients who are not candidates for transplantation due to age, comorbidities, or other criteria.

The incidence of heart failure, particularly among the elderly has contributed to the demand for LVADs. As the world's population ages, the prevalence of heart failure is predicted to climb creating a higher demand for advanced treatments such as LVADs. Furthermore, technological advances in LVAD design have resulted in smaller, more efficient, and easier-to-implant devices lowering surgical risks while increasing patient outcomes. Wireless power transfer and better biocompatible materials have improved the safety and endurance of LVADs making them more appealing to patients and healthcare professionals.

Will the Ongoing Research and Development Drive the Technology Segment?

Continuous flow technology has emerged as the dominant force, owing to major improvements over prior pulsatile flow systems. Continuous flow artificial hearts use a continuous, non-pulsatile mechanism to pump blood throughout the body providing several significant benefits that make them the favored choice in the medical profession. One of the key advantages is their tiny size which enables easier implantation in a broader range of patients including those with lower body proportions. This downsizing has made the technology more accessible and minimally intrusive resulting in better patient outcomes and shorter recovery periods.

Furthermore, continuous flow devices are noted for their long lifespan. Because they work on a consistent, continuous basis without the need for moving elements to contract and expand like normal heartbeats, Continuous flow technology not only leads the artificial heart market but it also symbolizes the future of cardiac support systems. Continuous research and development in this area improves the performance and reliability of these devices, further distinguishing them from their pulsatile predecessors. The medical community's choice of continuous flow devices is also influenced by the larger trend toward minimally invasive and long-lasting cardiac care solutions. This trend is likely to continue as technology advances ensuring that continuous flow artificial hearts stay at the forefront of life-saving cardiac procedures.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in the North American Region?

The North American region, particularly the United States and Canada is well-positioned to dominate the artificial heart industry due to its advanced healthcare infrastructure and significant investments in medical technology. North America, notably the United States, has some of the world's most complex healthcare systems with cutting-edge medical facilities, robust research and development skills, and significant investment in healthcare technology. These variables work together to produce an atmosphere that encourages the acceptance and development of advanced medical equipment such as artificial hearts.

The North American market benefits from an established regulatory structure that facilitates the approval and marketing of breakthrough medical innovations. The US Food and Drug Administration (FDA) is an important player in this process ensuring that new medical devices fulfill high safety and efficacy requirements before they are released to the market. This stringent approval process, though difficult, ultimately contributes to the trust and confidence that healthcare providers and patients have in these devices. The availability of significant funding and payment options for sophisticated cardiac treatments makes artificial hearts more accessible to patients, which drives market growth. Furthermore, the region's aging population, which is increasingly susceptible to heart-related ailments raises the need for effective cardiac support systems.

Will the Demand for Advanced Cardiac Therapies Drive the Market in the Asia Pacific Region?

The Asia Pacific region is expected to be the fastest-growing artificial heart market owing to increased cardiovascular disease prevalence and healthcare expenditure. This rapid expansion is primarily attributable to the vast population base, improved healthcare infrastructure, and increased awareness of innovative cardiac therapy in nations such as China, Japan, and India.

The demand for innovative cardiac therapy in Asia Pacific is projected to drive the artificial heart industry. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of mortality worldwide claiming an estimated 17.9 million lives per year. In the Western Pacific region which includes many Asian countries, cardiovascular diseases account for 35% of all deaths.

The increased frequency of CVD combined with an aging population is driving significant demand for sophisticated cardiac treatments including artificial hearts. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Asia and the Pacific's elder population is predicted to grow from 630 million in 2020 to approximately 1.3 billion by 2050. This demographic transition is projected to increase the incidence of heart failure, and thus the demand for artificial hearts. Furthermore, increased healthcare spending in the region is encouraging the use of modern medical technologies.

Competitive Landscape

The Artificial Heart Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the artificial heart market include:

Jarvik Heart, Inc.
BiVACOR, Inc.
CARMAT SA
SynCardia Systems, LLC
MyLVAD
Thoratec Corporation
Cirtec
Abbott
ON-X LIFE TECHNOLOGIES, INC.
ABIOMED
Cleveland Heart, Inc.
Tianjin Medical
Braile Biomedica
Edwards Lifesciences
R. Bard, Inc.
Terumo Corporation
MAQUET GmbH & Co. KG
Sorin Group
Medtronic, Inc.

Latest Developments

In September 2023, Abbott (NYSE: ABT) announced the completion of its acquisition of Bigfoot Biomedical, a market leader in the creation of smart insulin control devices for diabetics.